Combination Treatment for Melanoma Spread to Liver
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread to your liver (confirmed by biopsy).
- You have had 0 or 1 prior treatment for advanced melanoma (including immunotherapy or targeted pills).
- Your weight is at least 35 kilograms (about 77 pounds).
- Your organs are working well based on blood tests done in the last month.
- You have not taken HEPZATO KIT or Opdualag before.
- You do not have uncontrolled brain metastases or require high-dose steroids.
- You have not had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.
This trial tests a combination of treatments for melanoma that has spread to the liver after standard treatment. It uses freezing (cryoablation), a targeted drug (lenvatinib), chemotherapy (dacarbazine), and two immunotherapy drugs to try to shrink liver tumors and control the cancer. The goal is to see if this combined approach is safe and effective for patients whose cancer has not responded to prior therapy.
This trial is testing a combination of two drugs (pembrolizumab and odetiglucan) for people with colon or rectal cancer that has spread mainly to the liver. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) with standard chemotherapy (gemcitabine and cisplatin) for a rare type of liver cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.